Highland Therapeutics Announces Appointment of Craig S. Lewis to Board of Directors

TORONTO--()--Highland Therapeutics Inc. (“Highland”) today announced that its U.S. subsidiary, Ironshore Pharmaceuticals (America) Inc. (“IPA”), has appointed Craig S. Lewis to its Board of Directors. Mr. Lewis brings a proven track record to IPA along with a wealth of commercial leadership and strategy experience gained during a 30+ year career in the pharmaceutical and medical device industries.

Commenting on the appointment, Mr. David Lickrish, President & CEO of Highland stated, “I have had the great pleasure of knowing Craig over the past year and I have been impressed by his deep commitment to helping people realize their potential by building high-performance, cross-functional teams. This, along with his process-orientated approach and continuous push for innovation are the traits we want embedded within the DNA of our commercial organization. To have Craig on our Board to contribute his expertise is critical to achieving this objective.”

Mr. Lewis currently serves as the Senior Vice President, Chief Marketing & Strategy Officer for Assurex Health, an industry-leading precision medicine company providing treatment decision support to health care providers for behavioral health conditions, where he is an integral member of the firm’s leadership team. Prior to this, Mr. Lewis served as the Senior Vice President, Global Business Insights and Commercial Operations at Shire Pharmaceuticals (“Shire”). During his 12-year tenure at Shire, Mr. Lewis served as Vice President, U.S. Marketing and was appointed to the position of Senior Vice President and ADHD Business Unit Leader. In that capacity, Mr. Lewis helped to spur revenue growth in excess of 50% over a two-year period; achieving annual sales of approximately US$1.5 billion. Mr. Lewis has also held key commercial roles at Otsuka America Pharmaceutical, Zimmer/Seabrook Medical Systems and Marion Merrell Dow.

Commenting on his appointment, Mr. Lewis said, “Ironshore’s novel approach to drug development, in conjunction with its focus on improving the patient experience, parallel my own views and are a natural fit with my experience in the ADHD category. This is a unique opportunity to have a meaningful impact on improving patient care and I am delighted to join the Board of this exceptional organization.”

Mr. Lewis holds a Bachelor of Business Administration degree from the Carl H. Lindner College of Business at the University of Cincinnati and a Master of Business Administration degree from Xavier University.

About Highland Therapeutics Inc.

Highland Therapeutics Inc. is a specialty pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. The Company’s lead product candidates, HLD-200 and HLD-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease – inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS® is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing control of ADHD symptoms immediately upon wakening and throughout the day.

Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.

For further information, please visit the Company’s website at www.highlandtherapeutics.com, or contact:

Nelson F. Isabel
Chief Financial Officer
(647) 260-7875

Forward-Looking Statements

This press release contains forward-looking information, which reflects Highland’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Highland’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Highland assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

Highland Therapeutics Inc.
Nelson F. Isabel
Chief Financial Officer
(647) 260-7875

Contacts

Highland Therapeutics Inc.
Nelson F. Isabel
Chief Financial Officer
(647) 260-7875